| First Author | Favilla C | Year | 2008 |
| Journal | J Neurosci | Volume | 28 |
| Issue | 51 | Pages | 13952-6 |
| PubMed ID | 19091983 | Mgi Jnum | J:143516 |
| Mgi Id | MGI:3827059 | Doi | 10.1523/JNEUROSCI.4986-08.2008 |
| Citation | Favilla C, et al. (2008) Chronic Galphas signaling in the striatum increases anxiety-related behaviors independent of developmental effects. J Neurosci 28(51):13952-6 |
| abstractText | Current research in the field of anxiety disorders is largely receptor-centric, leaving intracellular pathways largely unexplored. Galphas, the G-protein which stimulates adenylyl cyclase and L-type voltage-gated calcium channels, may be one intracellular molecule regulating anxiety-related behaviors as increased efficacy of Galphas signaling has been noted in patient populations that suffer from anxiety. We report here anxiety-related behaviors in two lines of transgenic mice expressing a constitutively active isoform of Galphas (or Galphas*). The first line expressed Galphas* throughout postnatal forebrain neurons, while the second line of mice conditionally expressed Galphas* selectively in the striatum (Galphas*(str) mice). In the open field, both lines of mice showed a significant preference for the periphery suggesting that expression of Galphas* in the striatum alone was sufficient to produce an anxiogenic phenotype. In the light/dark box, Galphas*(str) mice exhibited longer latencies to enter the light and spent significantly less time in the lit compartment. Similarly, Galphas*(str) mice showed longer latencies to enter the open quadrants and spent less time in the open quadrants of the elevated zero maze. Interestingly, these anxiety-related phenotypes were largely unrelated to developmental effects as mice expressing the Galphas*(str) transgene during development, but not at testing, were normal on most measures. These observations show that chronic Galphas signaling in the striatum is sufficient to trigger anxiety-related behaviors largely independent of developmental effects and suggest the cAMP pathway or L-type voltage-gated calcium channels may be viable targets for future pharmacological intervention in the treatment of anxiety disorders. |
